Lifecore Biomedical, Inc. (LFCR)

In December 2025, Lifecore Biomedical was added to the Nasdaq Biotech Index, signed a 10-year manufacturing deal, and secured a CDMO agreement. In November 2025, the company reported Q1 2026 earnings, posting a loss but exceeding revenue estimates, and participated in investor conferences. In October 2025, Lifecore reported Q3 2025 revenue increased year-over-year. In September 2025, KeyBanc granted Lifecore a Sector Weight rating. In August 2025, the company announced its fiscal year 2025 financial results and signed new programs with new customers. In July 2025, insider selling activity was reported. As of January 12, 2026, the stock price gained slightly but experienced a decline over the preceding ten days, with a 52-week trading range between $4.76 and $8.85.

Direct information regarding the seasonality of demand for Lifecore Biomedical's specific products and services is not explicitly detailed. However, revenue guidance mentions customer order timing as a factor, and the CFO noted that revenue for the second half of calendar year 2025 was expected to be up significantly due to timing and customer ordering patterns, suggesting fluctuations in revenue based on customer ordering cycles.

Lifecore Biomedical, Inc. (LFCR) is a fully integrated contract development and manufacturing organization (CDMO) specializing in sterile injectable products and medical devices, operating within the Healthcare sector, specifically in the Biotechnology: Pharmaceutical Preparations industry. The company develops, fills, and finishes sterile injectable pharmaceuticals in various formats and is a leading producer of pharmaceutical-grade sodium hyaluronate (HA). Lifecore provides end-to-end services encompassing formulation, analytical testing, regulatory support, and packaging.

Lifecore Biomedical, Inc. is headquartered in Chaska, Minnesota, United States, and operates three cGMP facilities in Chaska and Chanhassen, Minnesota. While its primary operations are in the U.S., Lifecore manufactures FDA-approved commercial products and holds certifications from regulatory bodies in Europe, Japan, and Brazil, as well as the International Organization for Standardization (ISO), indicating an international reach for its products and services.

In the past year, Lifecore Biomedical has maintained a generally positive brand reputation, highlighted by its position as a differentiated injectable CDMO with a strong foundation in high-grade hyaluronic acid. The company boasts a regulatory track record spanning over 40 years and has more than 20 commercial products. Recent positive events include a successful FDA inspection and positive customer audits. Its expanded manufacturing capabilities have more than doubled its output potential, further solidifying its market position. However, a federal securities class action against Lifecore Biomedical, Inc. and some of its officers has reached a settlement, which could impact perception.

Lifecore Biomedical, Inc.'s ownership structure includes institutional, retail, and individual investors. Institutional investors hold a significant portion of the company's stock. Major institutional shareholders include Wynnefield Capital Inc, Legion Partners Asset Management, LLC, Greenhaven Road Investment Management, L.P., 325 Capital Llc, BlackRock, Inc., Vanguard Group Inc, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Geode Capital Management, Llc, Grizzlyrock Capital, Llc, and Morgan Stanley. Individual and insider ownership also constitutes a notable portion, with Christopher S. Kiper and Nelson Obus identified as significant individual shareholders.